| human | Q5 |
| P496 | ORCID iD | 0000-0002-9949-6012 |
| P108 | employer | Sotiria Thoracic Diseases Hospital of Athens | Q21626598 |
| P735 | given name | Mina | Q1800085 |
| Mina | Q1800085 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q96684492 | A Global Respiratory Perspective on the COVID-19 Pandemic: Commentary and Action Proposals |
| Q28355722 | ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle |
| Q96226501 | ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice |
| Q64360540 | ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD |
| Q64447220 | ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy” |
| Q59336326 | Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries |
| Q42131359 | Activin-A co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses |
| Q38794789 | Activin-A is overexpressed in severe asthma and is implicated in angiogenic processes. |
| Q45892489 | Activin-A is up-regulated in severe asthma, attenuates allergic responses and is associated with angiogenesis. |
| Q42572587 | Air pollution and asthma in Athens. |
| Q51713332 | Airway and systemic eosinophilia in asthma: does site matter? |
| Q54948318 | An algorithmic approach for the treatment of severe uncontrolled asthma. |
| Q58614006 | An international perspective on hospitalized patients with viral community-acquired pneumonia |
| Q46873378 | An official American Thoracic Society and European Respiratory Society policy statement: disparities in respiratory health |
| Q26775872 | Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives |
| Q37167808 | Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study. |
| Q91998686 | Asthma rescue treatments, time to reboot |
| Q47677172 | Best of lung cancer session presented during ERS 2017 Chinese language day: lung cancer screening. |
| Q95561568 | Breathing for two: pregnancy, asthma and respiratory failure |
| Q33616522 | Circulating conventional and plasmacytoid dendritic cell subsets display distinct kinetics during in vivo repeated allergen skin challenges in atopic subjects. |
| Q26775236 | Clinical asthma phenotypes in the real world: opportunities and challenges |
| Q39524363 | Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. |
| Q42095488 | Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy |
| Q51911709 | Continuing medical education across Europe: the role of EBAP and the ERS in facing the challenges of life-long learning. |
| Q38509920 | Control of asthma in real life: still a valuable goal? |
| Q73919272 | Dependence of forced vital capacity manoeuvre on time course of preceding inspiration in patients with restrictive lung disease |
| Q30613061 | Detection of exacerbations in asthma based on electronic diary data: results from the 1-year prospective BIOAIR study |
| Q36085452 | Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients |
| Q84152617 | Diagnostic usefulness of 5 tumor-markers in patients with primary lung-cancer |
| Q83364437 | Differences in microsatellite DNA level between asthma and chronic obstructive pulmonary disease |
| Q38177376 | EAACI position statement on asthma exacerbations and severe asthma |
| Q91467512 | ERS Clinical Research Collaborations: underpinning research excellence |
| Q90449509 | ERS Presidential Summit 2018: multimorbidities and the ageing population |
| Q49150053 | ERS guidelines, statements and technical standards published in the ERJ in 2014: a year in review. |
| Q92993147 | ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions |
| Q89685221 | ESR/ERS statement paper on lung cancer screening |
| Q41952990 | ESR/ERS white paper on lung cancer screening. |
| Q51544855 | Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. |
| Q38915347 | Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. |
| Q39524371 | Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. |
| Q41054096 | Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial |
| Q44886706 | Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. |
| Q80547249 | Eosinophilic infiltration in the nasal mucosa of rhinitis patients: is it affected by the presence of asthma or the allergic status of the patients? |
| Q73738609 | Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis |
| Q42320566 | Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). |
| Q89099836 | Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement |
| Q36793901 | Evaluation and management of severe asthma. |
| Q47929252 | Exercise-induced flow limitation, dynamic hyperinflation and exercise capacity in patients with bronchial asthma. |
| Q34911176 | Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity. |
| Q45031378 | Frequent exacerbators--a distinct phenotype of severe asthma |
| Q44313820 | Future directions for the ERS: presidential plans. |
| Q40631611 | Grass pollen immunotherapy decreases the number of mast cells in the skin. |
| Q57085039 | IL-5 expression and release from human CD34 cells in vitro; ex vivo evidence from cases of asthma and Churg-Strauss syndrome |
| Q70153934 | Immunotherapy and allergic inflammation |
| Q53820837 | Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. |
| Q34170327 | Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. |
| Q38068945 | Inhaled corticosteroids in COPD: pros and cons. |
| Q92645761 | Inhaled corticosteroids in asthma and the need for universal health coverage |
| Q47665267 | Inhaler adherence in severe asthma: is there an electronic solution? |
| Q42210687 | Integrated care pathways for airway diseases (AIRWAYS-ICPs). |
| Q90093983 | Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement |
| Q83362041 | Letter to the editor--osteopontin levels in human asthma |
| Q47798558 | Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. |
| Q43297953 | Long-term prognosis of asthma is good--a 12-year follow-up study. Influence of treatment. |
| Q51578316 | Lung cancer screening white paper: a slippery step forward? |
| Q90316980 | Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline |
| Q42750912 | Mediastinal widening and miliary chest radiograph pattern in a middle aged man: could it be sarcoidosis? |
| Q55650643 | New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. |
| Q74326018 | Noninvasive measurement of mean alveolar carbon dioxide tension and Bohr's dead space during tidal breathing |
| Q47952354 | Novel Biomarkers in Severe Asthma. |
| Q91523592 | Oral steroids in asthma: a double-edged sword |
| Q28285703 | Osteopontin expression and relation to disease severity in human asthma |
| Q28298064 | Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets |
| Q28285010 | Osteopontin is increased in the bronchoalveolar lavage fluid and bronchial tissue of smoking asthmatics |
| Q57677554 | Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery |
| Q41199541 | Perception of symptoms and quality of life - comparison of patients' and physicians' views in the COPD MIRROR study |
| Q36101572 | Precursor B Cells Increase in the Lung during Airway Allergic Inflammation: A Role for B Cell-Activating Factor |
| Q47122354 | Preface from ERS President 2018 Mina Gaga and ERS Early-Career Member Committee Chair Lieuwe Bos. |
| Q57494716 | Preface from European Respiratory Society President 2018 Mina Gaga and European Respiratory Society Early-Career Member Committee Chair Lieuwe D. J. Bos |
| Q73276800 | Prevalence of asthma and asthma-like symptoms in Athens, Greece |
| Q46127674 | Pulmonologists and lung cancer: pivotal role in multidisciplinary approach |
| Q92888329 | Respiratory medicine is not gender blind |
| Q36380236 | Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features. |
| Q26740215 | Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) |
| Q44683157 | Severe asthma in adults: what are the important questions? |
| Q80173088 | Skin reactivity and local cell recruitment in human atopic and nonatopic subjects by CCL2/MCP-1 and CCL3/MIP-1alpha |
| Q48505941 | Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. |
| Q38995231 | T2-low asthma: current approach to diagnosis and therapy. |
| Q48029675 | Targeting immunoglobulin E in non-atopic asthma: crossing the red line? |
| Q43677062 | The European Respiratory Society evaluates its 2013-2018 strategic plan implementation |
| Q51285717 | The European Respiratory Society plans its future: the 2013-2018 strategic plan. |
| Q93376382 | The European Respiratory Society's 10 Principles for Lung Health |
| Q91467495 | The European Respiratory Society: ensuring excellence through education best practice |
| Q38198586 | The European initiative for quality management in lung cancer care. |
| Q98162820 | The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians |
| Q67514942 | The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects |
| Q47905337 | The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP). |
| Q51578338 | The quest for the grail: multidimensional efforts for understanding and targeting severe asthma. |
| Q73666990 | The usefulness of inflammatory markers in monitoring treatment responses in asthma |
| Q59273921 | Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe: Table 1– |
| Q37631983 | Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. |
| Q42329924 | Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why? |
| Q92890299 | Toward clinically applicable biomarkers for asthma: An EAACI position paper |
| Q92205135 | Towards precision medicine: CCL2, another brick in the wall? |
| Q35344151 | Towards tuberculosis elimination: an action framework for low-incidence countries |
| Q30217483 | Tuberculosis elimination: theory and practice in Europe |
| Q46433272 | Tuberculous effusion: ADA activity correlates with CD4+ cell numbers in the fluid and the pleura. |
| Q71322671 | Tumour necrosis factor, interleukin-1 and adenosine deaminase in tuberculous pleural effusion |
| Q44928710 | Unevenness of ventilation assessed by the expired CO(2) gas volume versus V(T) curve in asthmatic patients. |
| Q37801138 | Update on severe asthma: what we know and what we need. |
| Q101120455 | Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals |
| Q125463869 | What bothers severe asthma patients most? A paired patient–clinician study across seven European countries |
| Q79383713 | [Evaluation of clinical practices in asthma] |
Search more.